Theravance Biopharma Inc
TBPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$877.45M
Close$
$10.75
36.4% downside
Current Fair Value
36.4% downsideOvervalued by 36.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $877.45 Million |
|---|---|
| Enterprise Value | $696.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.1 |
| Beta | 0.17 |
| Outstanding Shares | 51,279,000 |
Return
| Return on Equity | 18.57% |
|---|---|
| Return on Assets | 11.45% |
| Return on Invested Capital | -0.01% |
Valuation & Multiples
| P/E Ratio | 7.48 |
|---|---|
| PEG | -6.75 |
| Price to Sales | 8.46 |
| Price to Book Ratio | 3.38 |
| Enterprise Value to Revenue | 6.67 |
| Enterprise Value to EBIT | -10878.99 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$22.49 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$21.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 1191.90% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 5,000▼ 99.15% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.44%▼ 84.25% |
|---|---|
| Total Invested | $117.18M▼ 85.59% |
| Investors Holding | 58▼ 121.00% |
ESG Score
No data
About Theravance Biopharma Inc
CEO: Rick Winningham